αααααβααΎαAMLX β’ NASDAQ
add
Amylyx Pharmaceuticals Inc
13.64$
12 ααΈααΆ, 11:47:40 AM ααααβααα -4 · USD · NASDAQ · ααα
ααααΈαααααΆααα·αααα½ααα»αααααΌα
ααΆαβα αα»αααΌααααααααααΆαα
α»ααααααΈαα
α’αΆαααα·α
αα·αααΈαα»α
14.93$
α
αααααααααααα
13.56$ - 14.53$
α
ααααααα½αααααΆαα
α»αααααα
3.11$ - 17.49$
ααΎαβαα»αβααΈααααΆα
1.52Β αααΈααΆα USD
ααα ααα½αααΌαααααα
1.00Β ααΆα
α’αα»ααΆα P/E
-
αα·αααααβααΆαααΆα
-
ααΆααααααΌαα
αααα
NASDAQ
αααα»αβααααααΆαβ
α α·ααααααααα»
αααΆαααΆαααααααΆααα
αααΌα
α
αααΌα
α
αααΌααα»ααα
| (USD) | ααααΌ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌα | β | β |
α
αααΆαααααα·ααααα·ααΆα | 98.84Β ααΆα | -12.09% |
α
αααΌααα»ααα | -33.00Β ααΆα | 12.11% |
ααααΆααα
αααααα»ααα | β | β |
βα
αααΌααα»αααβαααα»ααα½αααΆαα αα»α | -0.30 | 45.45% |
α
αααΌααα»ααααα»αααΆαααααΆαα αααα ααΆαααααα αα·αααΆαααΆααααααα | -36.50Β ααΆα | 9.87% |
α’ααααΆαααααααααΆαααααα·αααααΆα | -0.14% | β |
αααααΈαααα»ααα
ααααααααα»α
ααΆαααα½ααα»αααααΌαααα»α
| (USD) | ααααΌ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
ααΆα
αααααΆαα αα·αααΆααα·αα·αααααααααααααΈ | 316.98Β ααΆα | 79.59% |
ααααααααα»α | 332.64Β ααΆα | 71.79% |
ααΆαααα½ααα»αααααΌαααα»α | 27.39Β ααΆα | -5.14% |
ααΌαβααααα»α | 305.26Β ααΆα | β |
ααΆαα αα»αβαα·αβααΆααααΆαααα | 110.54Β ααΆα | β |
ααααααααααΉαααααα
| 5.37 | β |
ααα
ααααααΎαααααα | -26.32% | β |
ααα
ααααααΎααΎααα»α | -28.19% | β |
ααα αΌαβααΆα
αβααααΆααβ
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα
| (USD) | ααααΌ 2025info | ααΆαααααΆααααααΌαααΆαβααααΆα |
|---|---|---|
α
αααΌααα»ααα | -33.00Β ααΆα | 12.11% |
ααΆα
αααααΆααααΈααααα·ααααα·ααΆα | -27.90Β ααΆα | 52.71% |
ααΆα
αααααΆααααΈααΆααα·αα·ααα | 29.47Β ααΆα | -54.65% |
ααΆα
αααααΆααααΈα α·ααααβαααααΆα | -208.00Β ααΆαα | -289.09% |
ααΆααααααααα½αβααΆα
αααααΆαααα»ααα | 1.48Β ααΆα | -73.46% |
ααα αΌαααΆα
αααααΆααααααα | -17.15Β ααΆα | 62.43% |
α’αααΈ
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
ααΆααααααΎαα‘αΎα
2013
αααααβαααααΆα
αα»ααααα·α
136
